- A Case of Subdural Empyema Mimicking Subdural Hemorrhage
-
Nam Oh Kim, Jung Ju Lee, Jong Moo Park, Byung Kun Kim, Ohyun Kwon, Woong Woo Lee, Kyusik Kang
-
Published online June 30, 2019
-
-
-
 Abstract
 PDF
- 경막하출혈을 닮은 경막하축농
- 긴장형 두통
-
Jin Young Ahn, Byung Kun Kim
-
Korean J Headache. 2009;10(1):35-46. Published online June 30, 2009
-
-
-
Abstract
PDF
- Tension-type headache (TTH) is the most common type of primary headache disorder. However TTH is an ill-defined and heterogeneous syndrome, which is diagnosed mainly be the absence of features of other headache disorders especially migraine. Despite the high prevalence and impact, knowledge about pathogenesis of TTH is still limited. Peripheral myofascial mechamism and central pain processing mechanism are implicated but their role in pathogenesis of TTH varies with the frequency of headache and among patients. Chronic tension type headache differs from episodic form in frequency, lack of response to treatment, more medication overuse, and more impact on quality of life.
- 자가편두통 선별 도구의 개발 및 타당도 평가 -한국 편두통 선별 설문-
-
Min-Kyung Chu, Byung Kun Kim, Sung Taek Kim, Jae-Moon Kim, Heui-Soo Moon, Jeong Wook Park, Kwang-Soo Lee, Kyung-Mi Oh, Jae-Myun Chung, Chin-Sang Chunge
-
Korean J Headache. 2007;8(2):84-91. Published online December 31, 2007
-
-
-
Abstract
PDF
- Background
Migraine is a common and disabling illness. But substantial migraine sufferers were underdiagnosed or undiagnosed. To improve migraine diagnosis, Korean Migraine Screening Questionnaire(KMSQ) was developed and validated in outpatient setting. Methods: A total of 507 patients who visited out patient clinic for headache were recruited in 10 hospitals in Korea and asked 10-item questionnaire concerning headache. 487 completed and returned the questionnaire. All patients were evaluated for headache and diagnosed by headache experts. Migraine diagnosis was assigned on International Head- ache Society(IHS) criteria after completing semi-structured diagnostic interview. Results: Of ten diagnostic questions derived from IHS criteria and headache expert experience, three-item subsets were deduced. Combination of questions regarding nausea, pulsating quality and photophobia showed optimum perfor- mances. Any two from the three items showed a sensitivity of 0.74, a specificity of 0.80, a positive predictive value of 80.8 and a negative predictive value of 73.5. Conclusion: The three-item Korean Migraine Screening Questionnaire was a valid and reliable migraine screening instru- ment in outpatient setting. It could help in improvement of migraine diagnosis and enhance migraine management.
- 두통 환자에서 뇌영상의 진단적 가치
-
Byung Kun Kim
-
Korean J Headache. 2007;8(1):16-19. Published online June 30, 2007
-
-
-
Abstract
PDF
- A complete headache history with neurological examinations will usually suffice to diagnose the majority of headaches without the need for diagnostic brain imaging. Headache is generally classified into the primary headaches, which are considered to have no other causative disorder, and the secondary headaches, which have organic causes. Neuroimaging testing, computed tomography(CT) scan, and magnetic resonance imaging(MRI) are useful for differential diagnosis and can perform to rule out vascular malformation, brain tumor, and other pathologies. There are cases of the secondary headaches resembling the primary headache and patients complaint of pain by complex of them. This article reviews general indications and studies available for brain imaging in patients with headache and normal neurological examination.
- 편두통 치료의 병태생리적 접근
-
Byung Kun Kim
-
Korean J Headache. 2005;6(1):6-13. Published online June 30, 2005
-
-
-
Abstract
PDF
- The pathophysiology of migraine is not fully understood. Neuronal hyperexcitability can explain the interictal status of migraine. Cortical spreading depression appears to underlie the aura phase in patients with migraine aura. The pain of the headache phase is mediated by the trigeminal vascular system and central projection. Preventive medications may target brain excitability, consequently blocking triggers of aura or headache. Acute medications inhibit trigeminal activation from either a peripheral or central location. Triptans ameliorate migraine headache primarily by constricting the dilated cranial blood vessels and by inhibiting the neurogenic inflammation. Recently published clinical study has reported that a selective CGRP receptor antagonist is effective in treating acute migraine attacks without significant side effects. Several new targets will be reviewed in this article. Korean Journal of Headache 6(1):6-13, 2005
- 가바펜틴에 의한 신경병증 통증의 치료:시판후 조사 결과
-
Byung Kun Kim
-
Korean J Headache. 2004;5(2):129-138. Published online December 31, 2004
-
-
-
Abstract
PDF
- Background
Neuropathic pain is initiated or caused by a primary lesion or dysfunction in the nervous system. Current treatment modalities on neuropathic pain are often ineffective. Gabapentin, an anticonvul- sant, has become the first choice in the treatment of neuropathic pain. This study evaluated tolerability and efficacy of gabapentin therapy on neuropathic pain in routine clinical practice. Method: A multicenter, prospective, noncomparative, open label clinical trial was performed. 45 neu- rologists from 40 hospitals were participated in this study. A total of 1,202 adult patients(592 males, 610 females, mean age 59.0 years) with neuropathic pain entered the trial. Efficacy of gabapentin was evalua- ted in 1,017 patients after a minimum of 6 weeks of treatment. Results: Most patients were started on a dose of 300mg/day and mean maximum dosage was 874 mg/day. The average duration of treatment was 75.4 days. A total of 86 patients experienced 103 adverse events. The most frequent adverse events were dizziness(3.1%) and drowsiness(1.7%). Among 1,017 patients, physicians' clinical global improvement was 'markedly improved' in about 21% of patients, 'moderately improved' in about 40% and 'minimally improved' in about 26%. Mean daily pain score based on an 11-point Likert scale from baseline week to the final week of treatment was significantly reduced from 6.1 to 3.2(p<0.0001). Sleep interference score was also significantly reduced from 3.3 to 1.7(p<0.0001). Conclusions: The results of this study, performed in a real situation of clinical practice, confirmed safety and effectiveness of gabapentin in the treatment of neuropathic pain. Korean Journal of Headache 5(2):129-138, 2004
- Treatment of Neuropathic Pain with Gabapentin: Results of A Post-marketing Surveillance Study
-
Byung Kun Kim
-
Korean J Headache. 2004;5(1):106-106. Published online June 30, 2004
-
-
-
Abstract
PDF
- Background
Neuropathic pain is initiated or caused by a primary lesion or dysfunction in the nervous system. Current treatment modalities on neuropathic pain are often ineffective. Gabapentin, an anticonvul- sant, has become the first choice in the treatment of neuropathic pain. This study evaluated tolerability and efficacy of gabapentin therapy on neuropathic pain in routine clinical practice. Mesthod: A multi-center, open label, prospective, uncontrolled clinical trial was performed. Forty-five neurologists from 40 hospitals were participated in this study. A total of 1,202 adult patients(592 male, 610 female, mean age 59.0 years) with neuropathic pain entered the trial. Efficacy of gabapentin was evaluated in 1,017 patients after a minimum of 6 weeks of treatment. Results: Most patients were started dosage of 300mg/day and mean maximum dosage was 874mg/day. The average duration of treatment was 75.4 days. A total of 86 patients experienced 103 adverse events. The most frequent adverse effects were dizziness(3.1%) and drowsiness(1.7%). Among 1,017 patients, clinical global improvement was 'markedly improved' in about 21% of patients, 'moderately improved' in 40% and 'minimally improved' in about 26%. Mean daily pain score based on an 11-point Likert scale from baseline week to the final week of treatment was significantly reduced from 6.1 to 3.2(p<0.0001). Sleep interference score was also significantly reduced from 3.3 to 1.7(p<0.0001). Conclusions: The results of this study, performed in a real situation of clinical practice, confirmed safety and effectiveness of gabapentin in the treatment of neuropathic pain. Korean Journal of Headache 5(1):106-106, 2004
|
KHS
